Repeated oral treatment with polysaccharide sulfate reduces insulin resistance and dyslipidemia in diabetic dyslipidemic rat model
- VernacularTitle:藻酸双酯钠改善模型大鼠的胰岛素抵抗和血脂异常
- Author:
Meimi ZHAO
;
Zhi LI
;
Zan TENG
;
Jinsheng ZHAO
;
Xiuhua YU
;
Yasuo WATANABE
;
Limei ZHAO
- Publication Type:Journal Article
- Keywords:
polysaccharide sulfate;
experimental diabetes mellitus;
streptozotocin;
dyslipidemia
- From:
Acta Pharmaceutica Sinica
2007;42(5):488-491
- CountryChina
- Language:Chinese
-
Abstract:
Polysaccharide sulfate (PSS) is a new type of antiatherosclerotic medicine for its effects of anticoagulation, anti-thrombosis and modulation of dyslipidemia. However, it is still uncertain whether PSS could modulate the diabetic dyslipidemia or not. Here, the rat model of diabetic dyslipidemia was developed and the effects of PSS on glucose and lipid levels were investigated in this animal model. Wistar rats were iv injected with streptozotocin 20 mg·kg-1 after feeding with high fat diet for one and a half month. Then, rats received orally PSS (30, 90, and 180 mg·kg-1) for 1 month. After oral treatment with PSS (90 and 180 mg·kg-1) for 1 month, the levels of triglyceride (TG), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C) were significantly reduced and the level of high density lipoprotein-cholesterol (HDL-C) increased, compared with diabetic control rats. Moreover, PSS (30, 90, and 180 mg·kg-1) had a tendency to reduce glucose and insulin levels, and significantly increased insulin sensitivity index. Our results suggest that PSS could improve insulin sensitivity and relieve dyslipidemia in diabetic dyslipidemic rats.
